[HTML][HTML] Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis
L Campiotti, MB Suter, L Guasti, R Piazza… - European Journal of …, 2017 - Elsevier
Abstract Purpose Tyrosine kinase inhibitors (TKIs) are the cornerstones of treatment for
patients with chronic myeloid leukaemia (CML). In recent years, several studies were …
patients with chronic myeloid leukaemia (CML). In recent years, several studies were …
Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
FX Mahon, G Etienne - Clinical Cancer Research, 2014 - AACR
Chronic myeloid leukemia (CML) is caused by formation of the BCR–ABL1 fusion protein.
Tyrosine kinase inhibitors (TKI) that target BCR–ABL1 are now the standard of care for …
Tyrosine kinase inhibitors (TKI) that target BCR–ABL1 are now the standard of care for …
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
NCLscan: accurate identification of non-co-linear transcripts (fusion, trans-splicing and circular RNA) with a good balance between sensitivity and precision
Abstract Analysis of RNA-seq data often detects numerous 'non-co-linear'(NCL) transcripts,
which comprised sequence segments that are topologically inconsistent with their …
which comprised sequence segments that are topologically inconsistent with their …
Detection of gene mutations and gene–gene fusions in circulating cell‐free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis
Glioblastoma (GBM) is the most common type of glioma and is uniformly fatal. Currently,
tumour heterogeneity and mutation acquisition are major impedances for tailoring …
tumour heterogeneity and mutation acquisition are major impedances for tailoring …
targeting Primitive chronic Myeloid leukemia cells by effective inhibition of a New AHi-1–Bcr-ABl–JAK2 complex
M Chen, P Gallipoli, D DeGeer, I Sloma… - Journal of the …, 2013 - academic.oup.com
Background Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia
(CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with BCR-ABL …
(CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with BCR-ABL …
Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment
Histiocytic sarcoma (HS) is an extremely rare non‐Langerhans cell disorder with an
aggressive course and limited treatment options. Recent advances in molecular/genetic …
aggressive course and limited treatment options. Recent advances in molecular/genetic …
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
M Horn, I Glauche, MC Müller… - Blood, The Journal …, 2013 - ashpublications.org
Molecular response to imatinib (IM) in chronic myeloid leukemia (CML) is associated with a
biphasic but heterogeneous decline of BCR-ABL transcript levels. We analyzed this …
biphasic but heterogeneous decline of BCR-ABL transcript levels. We analyzed this …
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Approximately half of patients with chronic myeloid leukemia (CML) in sustained deep
molecular response who discontinue tyrosine kinase inhibitors (TKIs) remain in treatment …
molecular response who discontinue tyrosine kinase inhibitors (TKIs) remain in treatment …
[HTML][HTML] Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic …
In chronic myelogenous leukemia (CML), treatment-free remission (TFR) is defined as
maintaining a major molecular response (MMR) without a tyrosine kinase inhibitor (TKI) …
maintaining a major molecular response (MMR) without a tyrosine kinase inhibitor (TKI) …